Rare hematology
Hematologic, or blood-related diseases, can disrupt essential processes in the body and lead to life-threatening complications.1 Alexion’s hematology research seeks to develop innovative treatments that address underlying blood disorders and improve survival and quality of life.
Recruiting trials
Hematology
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (ALACRITY)
More informationHematology
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (I TRANSCEND)
More informationHematology
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
More information
Turning research into real impact
Our commitment to hematology builds on years of experience pioneering treatments for rare blood diseases.
-
Understanding complex immune and genetic drivers
We study how immune system imbalances lead to serious blood disorders.
-
Creating next-generation treatments
Alexion is advancing investigational therapies to restore balance in blood production and immune response.
-
Partnering with hematology experts worldwide
Collaboration ensures that our science translates into real progress for patients with the rarest and most challenging conditions.
References
- my.clevelandclinic.org/health/diseases/21545-blood-disorders
